Skip to content
Brand Logo

Forum
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
  • Jennifer CarrollJ

    PAAB Forum Quarterly Review and eFiles Tag and CEI Report - Q2/2024

    Blogs external newsletter cei tag
    1
    1 Votes
    1 Posts
    578 Views
    No one has replied
  • D

    "Exclusive rights to ad placement" for digital media/banner ads

    Electronic Media
    2
    0 Votes
    2 Posts
    750 Views
    Jennifer CarrollJ
    Good afternoon @dmauri Please see the PAAB Advisory on Disclosure of APS Placement Details. The answer will be dependent on the ad and where it is being placed. A general question you could ask yourself is, “Am I creating a link between the brand and articles which may be considered off-label by virtue of exclusive placement?”. Note that the concern is the potential for placement to create a notable link between the brand and articles/content on the page(s) which could exceed the federal advertising regulations. This potential is amplified by exclusivity of ad placement.